01 feb: Alm. Brand A/S – Økonomidirektør skifter til nyt job
01 feb: Coloplast leverer tilfredsstillende kvartalsregnskab på linje med..
01-02-2017 12:00:00

Announcement no. 1 - Interim Financial Report, Q1 2016/17

Relateret indhold
21 jul - 
Fredagens aktier: Mærsk, Novo og FLSmidth sendte C20 ti..
21 jul - 
Aktier/middag: FLSmidth får stryg og tager bunden i C20
13 jul - 
Torsdagens aktier: Nets i uvant rekordrolle i roligt ma..
Relateret debat
12 jul - 
Du er formentlig glad for, du ikke fik sat den short ;)..
09 jul - 
Jeg trækker bare Coloplast frem i lyset, fordi je..
09 jul - 
Coloplast er ikke en særlig sexet aktie, så jeg holder ..

Highlights

·       Organic revenue growth was 6%. Revenue in DKK was up by 3% to DKK 3,755m.

·       Organic growth rates by business area: Ostomy Care 6%, Continence Care 5%, Urology Care 8% and Wound & Skin Care 5%.

·       As expected, growth in the US Chronic Care business was adversely affected by inventory reductions at large distributors, and inventory levels are now back to normal.

·       The South Korean healthcare authorities have enhanced subsidy schemes for intermittent catheters effective 1 January 2017 to cover approximately 25,000 South Koreans.

·       The acquisition of US distributor Comfort Medical was approved at the end of December at a value of DKK 1.1bn.

·       Management estimates that more than 95% of the lawsuits in the US alleging injury resulting from the use of transvaginal surgical mesh products designed to treat pelvic organ prolapse and stress urinary incontinence have been settled at the date of this report.

·       EBIT was up by 3% measured in DKK and 8% at constant exchange rates, to DKK 1,226m. The EBIT margin was 33% at constant exchange rates, against 32% last year. Measured in DKK, the EBIT margin was 33%, which was in line with the year-earlier period.

·       The net profit for the reporting period was up by 15% to DKK 946m, while diluted earnings per share were also up by 15% to DKK 4.46.

·       The free cash flow was negative at DKK 833m, DKK 1,664m less than in the same period of last year. Adjusted for payments made in connection with lawsuits alleging injury resulting from the use of transvaginal surgical mesh products and the acquisition of Comfort Medical, the free cash flow was an inflow of DKK 1,439m against DKK 1,284m in Q1 2015/16.

·       The second part of the share buy-back programme totalling DKK 1bn running until the end of the 2016/17 financial year is expected to be launched in Q2 2016/17.

 

Financial guidance for 2016/17

·       We expect revenue growth of 7-8% at constant exchange rates and of 7-8% in DKK.

·       We expect an EBIT margin of 33-34%, at constant exchange rates and of about 33% in DKK.

·       Capital expenditure is expected to be about DKK 700m.

·       The effective tax rate is expected to be about 23%.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Fondsbørsmeddelelser

GE Wind solgte igen færre vindmøller i andet kvartal

21-07-2017 13:02:07
General Electric (GE) havde igen et fald i antallet af bestilte og afskibede vindmøller i andet kvartal i GE Wind-forretningen, der er en af Vestas' store konkurrenter.GE Winds ordreindgang faldt til 567 møller fra 637 i samme kvartal for et år siden, og der blev sendt 757 afsted til kunderne mod 856 i andet kvartal af 2016.Det var andet kvartal i træk med fald i ordrerne og tredje i træk med et l..

Aktier/middag: FLSmidth får stryg og tager bunden i C20

21-07-2017 11:42:46
FLSmidth er under pres på et positivt dansk aktiemarked, der fredag er præget af sommerferie med begrænset volumen og nyhedsstrøm.Den danske ingeniørkoncern er i fokus, da den finske rival Metso har offentliggjort et svagt regnskab for andet kvartal, hvor driftsoverskuddet på 59,8 mio. euro var et stykke fra det ventede plus på 78 mio. euro.Et positivt element var dog, at forventningerne til efter..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Vestas henter amerikansk ordre på 200 MW - NY
2
Aktier/middag: FLSmidth får stryg og tager bunden i C20
3
Fredagens aktier: Mærsk, Novo og FLSmidth sendte C20 til tælling
4
Danske Bank/Jyske: Tror stadig på større overskud end banken selv
5
Dansk økonom udpeget til topstilling i fransk storbank

Relaterede aktiekurser

Coloplast B A/S 552,00 2,6% Stigning i aktiekurs
Coloplast 85,70 3,3% Stigning i aktiekurs

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2017  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
22. juli 2017 08:41:47
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20170720.2 - EUROWEB1 - 2017-07-22 08:41:47 - 2017-07-22 08:41:47 - 1 - Website: OKAY